AJT 240

Drug Profile

AJT 240

Alternative Names: AJT-240

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EA Pharma
  • Developer EA Pharma; JW Pharmaceutical
  • Class
  • Mechanism of Action Calcium-sensing receptor agonists; Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Secondary hyperparathyroidism

Most Recent Events

  • 31 Oct 2017 JW Pharmaceutical in-licenses AJT 240 from EA Pharma
  • 31 Oct 2017 Clinical trials in Secondary hyperparathyroidism in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top